The IgG2 isotype, often described as a poor mediator of ADCC since it only binds to activatory CD32a (Schneider-Merck et al., 2010), efficiently depleted tumor-infiltrating Treg cells in vivo (Treg/total CD4+ T cells = 13%), with comparable activity to that observed in mice treated with the IgG1 and IgG1SDALIE isotype variants. This evidence concerns the gene CD4 and neoplasm.